Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals (CRNX) has announced new stock option grants under its 2021 Employment Inducement Incentive Award Plan. The company granted options to purchase 96,100 shares to sixteen new non-executive employees and 100,000 shares to one new executive employee on January 10, 2025.
The options were granted at an exercise price of $40.59 per share, matching Crinetics' closing price on The Nasdaq Global Select Market. The vesting schedule spans four years, with 25% vesting after one year and the remaining shares vesting in 36 equal monthly installments, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement awards for new employees.
Crinetics Pharmaceuticals (CRNX) ha annunciato nuove concessioni di opzioni su azioni nell'ambito del suo Piano di Incentivazione per l'Occupazione del 2021. L'azienda ha concesso opzioni per l'acquisto di 96.100 azioni a sedici nuovi dipendenti non esecutivi e 100.000 azioni a un nuovo dipendente esecutivo il 10 gennaio 2025.
Le opzioni sono state concesse a un prezzo di esercizio di 40,59 $ per azione, corrispondente al prezzo di chiusura di Crinetics sul Nasdaq Global Select Market. Il programma di maturazione si estende per quattro anni, con il 25% che matura dopo un anno e le rimanenti azioni che maturano in 36 rate mensili uguali, a condizione di un'occupazione continuativa. Queste concessioni sono state effettuate in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) come premi di incentivazione per i nuovi dipendenti.
Crinetics Pharmaceuticals (CRNX) ha anunciado nuevas concesiones de opciones sobre acciones bajo su Plan de Incentivación para Empleo 2021. La compañía otorgó opciones para comprar 96,100 acciones a dieciséis nuevos empleados no ejecutivos y 100,000 acciones a un nuevo empleado ejecutivo el 10 de enero de 2025.
Las opciones se concedieron a un precio de ejercicio de $40.59 por acción, correspondiente al precio de cierre de Crinetics en el Nasdaq Global Select Market. El calendario de adquisición se extiende por cuatro años, con un 25% adquiriendo derechos después de un año y las acciones restantes adquiriendo derechos en 36 cuotas mensuales iguales, sujeto a una continua ocupación. Estas concesiones se realizaron de acuerdo con la Regla de Inscripción de Nasdaq 5635(c)(4) como premios de inducimiento para nuevos empleados.
크리네틱스 제약(CRNX)은 2021년 고용 유도 인센티브 보상 계획에 따라 새로운 스톡 옵션 부여를 발표했습니다. 회사는 2025년 1월 10일에 16명의 새로운 비상임 직원에게 96,100주의 구매 옵션을, 그리고 1명의 새로운 임원에게 100,000주의 구매 옵션을 부여했습니다.
옵션은 주당 $40.59의 행사 가격으로 부여되었으며, 이는 크리네틱스의 나스닥 글로벌 셀렉트 시장에서의 종가와 일치합니다. 취득 일정은 4년에 걸쳐 있으며, 1년 후 25%가 취득되고 나머지 주식은 계속된 근무 조건 하에 36개월에 걸쳐 균등하게 취득됩니다. 이러한 부여는 새로운 직원에 대한 유도 보상으로 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Crinetics Pharmaceuticals (CRNX) a annoncé de nouvelles concessions d'options d'achat d'actions dans le cadre de son Plan d'Attribution d'Incentives à l'Emploi de 2021. La société a accordé des options d'achat de 96 100 actions à seize nouveaux employés non exécutifs et 100 000 actions à un nouvel employé exécutif le 10 janvier 2025.
Les options ont été accordées à un prix d'exercice de 40,59 $ par action, correspondant au prix de clôture de Crinetics sur le Nasdaq Global Select Market. Le calendrier de vesting s'étale sur quatre ans, avec 25 % qui acquièrent des droits après un an, et les actions restantes acquérant des droits par tranches mensuelles égales sur 36 mois, sous réserve d'un emploi continu. Ces attributions ont été effectuées conformément à la Règle de Cotation Nasdaq 5635(c)(4) en tant que prix d'incitation pour les nouveaux employés.
Crinetics Pharmaceuticals (CRNX) hat neue Aktienoptionsvergaben im Rahmen seines Anreizplans für die Beschäftigung von 2021 bekannt gegeben. Das Unternehmen hat am 10. Januar 2025 Optionen zum Kauf von 96.100 Aktien an sechzehn neue nicht-executive Mitarbeiter und 100.000 Aktien an einen neuen Executive Mitarbeiter vergeben.
Die Optionen wurden zu einem Ausübungspreis von 40,59 $ pro Aktie vergeben, was dem Schlusskurs von Crinetics am Nasdaq Global Select Market entspricht. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25% nach einem Jahr und die verbleibenden Aktien in 36 gleichen monatlichen Raten ausgezahlt werden, abhängig von der fortgesetzten Beschäftigung. Diese Vergaben wurden gemäß der Nasdaq-Notierungsregel 5635(c)(4) als Anreizvergaben für neue Mitarbeiter vorgenommen.
- Expansion of workforce with 17 new employees, including one executive
- Stock options aligned with market price, indicating fair compensation practice
- Potential future dilution of existing shareholders due to 196,100 new stock options
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,100 shares of its common stock to sixteen new non-executive employees and 100,000 to one new executive employee under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 450-6464
FAQ
How many shares were granted in CRNX's January 2025 inducement awards?
What is the exercise price for CRNX's January 2025 inducement stock options?
What is the vesting schedule for CRNX's January 2025 inducement grants?
How many new employees received CRNX stock options in January 2025?
